| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | AP13 |
| Uniprot No | P98170 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-497aa |
| 氨基酸序列 | TFNSFEGSKTCVPADINKEEEFVEEFNRLKTFANFPSGSPVSASTLARAGFLYTGEGDTVRCFSCHAAVDRWQYGDSAVGRHRKVSPNCRFINGFYLENSATQSTNSGIQNGQYKVENYLGSRDHFALDRPSETHADYLLRTGQVVDISDTIYPRNPAMYSEEARLKSFQNWPDYAHLTPRELASAGLYYTGIGDQVQCFCCGGKLKNWEPCDRAWSEHRRHFPNCFFVLGRNLNIRSESDAVSSDRNFPNSTNLPRNPSMADYEARIFTFGTWIYSVNKEQLARAGFYALGEGDKVKCFHCGGGLTDWKPSEDPWEQHAKWYPGCKYLLEQKGQEYINNIHLTHSLEECLVRTTEKTPSLTRRIDDTIFQNPMVQEAIRMGFSFKDIKKIMEEKIQISGSNYKSLEVLVADLVNAQKDSMQDESSQTSLQKEISTEEQLRRLQEEKLCKICMDRNIAIVFVPCGHLVTCKQCAEAVDKCPMCYTVITFKQKIFMS |
| 预测分子量 | 57 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是模拟生成的关于AP13重组蛋白的参考文献示例(注：实际文献可能需要通过学术数据库验证)：
---
1. **文献名称**: *Immunogenicity of a Recombinant AP13 Protein from Ancylostoma caninum in Murine Models*
**作者**: Goud, N.P. et al.
**摘要**: 研究评估了钩虫来源的AP13重组蛋白的免疫原性，表明其在小鼠模型中能诱导Th2型免疫反应，并降低幼虫移行率，提示其作为疫苗候选的潜力。
2. **文献名称**: *Structural Characterization and Functional Analysis of AP13. a Secreted Protein from Hookworm*
**作者**: Williamson, A.L. et al.
**摘要**: 通过X射线晶体学解析AP13蛋白的三维结构，发现其与宿主免疫调节分子相互作用，可能参与寄生虫免疫逃逸机制。
3. **文献名称**: *Optimization of AP13 Recombinant Protein Expression in E. coli for Antigen Discovery*
**作者**: Bian, S.R. et al.
**摘要**: 报道了在大肠杆菌系统中高效表达可溶性AP13蛋白的工艺优化，为大规模生产用于诊断或疫苗开发的抗原奠定基础。
4. **文献名称**: *AP13 as a Novel Target for Anti-parasitic Drug Development*
**作者**: Hotez, P.J. & Bethony, J.
**摘要**: 探讨AP13在寄生虫生命周期中的关键作用，并验证其作为药物靶点的可行性，为开发新型抗蠕虫疗法提供理论依据。
---
建议通过PubMed、Web of Science等平台，以关键词“AP13 recombinant protein”或“Ancylostoma AP13”检索最新文献以获取准确信息。
**Background of AP13 Recombinant Protein**
AP13 recombinant protein is a genetically engineered biomolecule designed for research and therapeutic applications. Derived from a specific antigenic or functional domain of a native protein, AP13 is typically produced using recombinant DNA technology. This involves cloning the gene encoding the target protein sequence into expression vectors (e.g., bacterial, yeast, or mammalian systems), followed by purification to ensure high specificity and activity.
The development of AP13 is often linked to studies on immune responses, particularly in infectious diseases or cancer. For instance, AP13 may originate from viral or bacterial pathogens as an antigenic epitope, enabling its use in diagnostic assays or subunit vaccine development. Its recombinant nature allows scalability, reproducibility, and reduced risk of contamination compared to native protein extraction.
In biomedical research, AP13 serves as a tool to investigate protein-protein interactions, cellular signaling pathways, or immune receptor engagement. Its application extends to therapeutics, such as monoclonal antibody production or targeted drug delivery systems. Structural modifications (e.g., fusion tags, solubility enhancers) are often incorporated to improve stability and functionality.
Challenges in AP13 production include optimizing expression conditions, minimizing post-translational heterogeneity, and ensuring biological activity post-purification. Ongoing advancements in bioengineering and bioprocessing continue to refine its applications, positioning AP13 as a versatile component in both basic science and clinical innovation.
×
